JP2015522573A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015522573A5 JP2015522573A5 JP2015519000A JP2015519000A JP2015522573A5 JP 2015522573 A5 JP2015522573 A5 JP 2015522573A5 JP 2015519000 A JP2015519000 A JP 2015519000A JP 2015519000 A JP2015519000 A JP 2015519000A JP 2015522573 A5 JP2015522573 A5 JP 2015522573A5
- Authority
- JP
- Japan
- Prior art keywords
- administered
- composition according
- composition
- glp
- agonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 17
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 claims 8
- 208000008589 Obesity Diseases 0.000 claims 2
- 230000037406 food intake Effects 0.000 claims 2
- 235000012631 food intake Nutrition 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000036186 satiety Effects 0.000 claims 2
- 235000019627 satiety Nutrition 0.000 claims 2
- DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical group CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229950011186 semaglutide Drugs 0.000 claims 1
- 108010060325 semaglutide Proteins 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12174535.0 | 2012-07-01 | ||
| EP12174535 | 2012-07-01 | ||
| US201261694837P | 2012-08-30 | 2012-08-30 | |
| US61/694,837 | 2012-08-30 | ||
| US201261708162P | 2012-10-01 | 2012-10-01 | |
| EP12186781 | 2012-10-01 | ||
| US61/708,162 | 2012-10-01 | ||
| EP12186781.6 | 2012-10-01 | ||
| PCT/EP2013/063004 WO2014005858A1 (en) | 2012-07-01 | 2013-06-21 | Use of long-acting glp-1 peptides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015522573A JP2015522573A (ja) | 2015-08-06 |
| JP2015522573A5 true JP2015522573A5 (cg-RX-API-DMAC7.html) | 2016-03-10 |
| JP6059802B2 JP6059802B2 (ja) | 2017-01-11 |
Family
ID=65858459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015519000A Active JP6059802B2 (ja) | 2012-07-01 | 2013-06-21 | 長時間作用型ｇｌｐ−１ペプチドの使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US9764003B2 (cg-RX-API-DMAC7.html) |
| EP (3) | EP3689365B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6059802B2 (cg-RX-API-DMAC7.html) |
| AU (3) | AU2013286177B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112014032938A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2877056A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK2866825T3 (cg-RX-API-DMAC7.html) |
| ES (2) | ES2796839T3 (cg-RX-API-DMAC7.html) |
| HR (2) | HRP20200889T1 (cg-RX-API-DMAC7.html) |
| HU (2) | HUE072859T2 (cg-RX-API-DMAC7.html) |
| MX (3) | MX376058B (cg-RX-API-DMAC7.html) |
| PL (2) | PL2866825T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT2866825T (cg-RX-API-DMAC7.html) |
| RS (2) | RS60432B1 (cg-RX-API-DMAC7.html) |
| RU (2) | RU2018117557A (cg-RX-API-DMAC7.html) |
| SI (1) | SI2866825T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014005858A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2651398T (pt) | 2010-12-16 | 2018-03-09 | Novo Nordisk As | Composições sólidas compreendendo um agonista de glp-1 e um sal de ácido n-(8-(2-hidroxibenzoil)amino) caprílico |
| MY161450A (en) | 2011-04-12 | 2017-04-14 | Novo Nordisk As | Double-acylated glp-1 derivatives |
| EP4324475A1 (en) | 2012-03-22 | 2024-02-21 | Novo Nordisk A/S | Compositions of glp-1 peptides and preparation thereof |
| CN104487056A (zh) | 2012-06-20 | 2015-04-01 | 诺和诺德A/S（股份有限公司） | 包含肽和递送剂的片剂制剂 |
| JP6059802B2 (ja) | 2012-07-01 | 2017-01-11 | ノヴォ ノルディスク アー／エス | 長時間作用型ｇｌｐ−１ペプチドの使用 |
| PL2991671T3 (pl) | 2013-05-02 | 2019-01-31 | Novo Nordisk As | Doustne dawkowanie związków glp-1 |
| KR102127624B1 (ko) * | 2014-10-16 | 2020-06-29 | 얀마 파워 테크놀로지 가부시키가이샤 | 작업 차량 |
| GB201621987D0 (en) * | 2016-12-22 | 2017-02-08 | Archer Virgil L See Archer Sheri A Arecor Ltd | Novel composition |
| DE102017106216A1 (de) * | 2017-03-22 | 2018-09-27 | Amw Gmbh | Extrudierte Depotform zur anhaltenden Wirkstofffreisetzung |
| TWI847306B (zh) | 2017-08-24 | 2024-07-01 | 丹麥商諾佛 儂迪克股份有限公司 | Ｇｌｐ-１組成物及其用途 |
| BR112020006246A2 (pt) * | 2017-10-12 | 2021-03-30 | Novo Nordisk A/S | Método para controle do peso de um sujeito em necessidade |
| GB201720187D0 (en) * | 2017-12-04 | 2018-01-17 | Imperial Innovations Ltd | Novel Compounds |
| JP6898518B2 (ja) | 2018-02-02 | 2021-07-07 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１アゴニスト、ｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩及び滑沢剤を含む固形組成物 |
| TWI705820B (zh) | 2018-06-22 | 2020-10-01 | 美商美國禮來大藥廠 | Gip/glp1促效劑組合物 |
| US20210162013A1 (en) * | 2018-08-03 | 2021-06-03 | Brown University | Compositions and methods for improving the bioavailability of glp1 and analogues thereof |
| WO2020176678A1 (en) * | 2019-02-26 | 2020-09-03 | Twist Bioscience Corporation | Variant nucleic acid libraries for glp1 receptor |
| AU2020377469A1 (en) * | 2019-11-06 | 2022-04-28 | Novo Nordisk A/S | GLP-1 receptor agonists in dementia |
| MX2022008139A (es) * | 2019-12-30 | 2022-10-03 | Gan & Lee Pharmaceuticals Co Ltd | Compuestos de glp-1 de acción prolongada. |
| PE20230819A1 (es) * | 2020-02-18 | 2023-05-19 | Novo Nordisk As | Composiciones y usos de glp-1 |
| CN112768087A (zh) * | 2020-12-23 | 2021-05-07 | 吉林大学 | 利用孟德尔随机化方法验证索马鲁肽口服制剂预防二型糖尿病的用途 |
| EP4359074A4 (en) * | 2021-06-24 | 2025-06-04 | Gila Therapeutics, Inc. | METHODS AND KITS FOR INDUCTING SATOURAGE AND TREATMENT OF METABOLIC DISEASES |
| US11865213B2 (en) * | 2021-07-05 | 2024-01-09 | Mapi Pharma Ltd. | Semaglutide depot systems and use thereof |
| MX2024003872A (es) | 2021-09-27 | 2024-04-19 | Terns Pharmaceuticals Inc | Acidos carboxilicos de benzimidazol como agonistas de glp-1r. |
| AU2022375634A1 (en) | 2021-10-25 | 2024-06-06 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| WO2023086499A1 (en) | 2021-11-10 | 2023-05-19 | I2O Therapeutics, Inc. | Ionic liquid compositions |
| CN114621339B (zh) * | 2021-12-28 | 2022-09-23 | 北京惠之衡生物科技有限公司 | 一种长效glp-1衍生物 |
| IL315151A (en) | 2022-02-23 | 2024-10-01 | Terns Pharmaceuticals Inc | Compounds as glp-1r agonists |
| WO2023225370A1 (en) * | 2022-05-19 | 2023-11-23 | Vault Bioventures, Inc. | Obesity treatment and prevention methods |
| EP4642440A1 (en) | 2022-12-30 | 2025-11-05 | Algipharma As | Compositions and methods to increase the systemic bioavailability of a polypeptide therapeutic agent undergoing oral administration |
| KR20250166323A (ko) | 2023-04-07 | 2025-11-27 | 테른스 파마슈티칼스, 인크. | 간 장애 또는 심장대사 질환의 치료에 사용하기 위한 thr베타 효현제 및 glp-1r 효현제를 포함하는 조합 |
| WO2025024455A1 (en) | 2023-07-24 | 2025-01-30 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for delivery of therapeutic peptides |
| WO2025165146A1 (ko) * | 2024-01-29 | 2025-08-07 | 주식회사 티온랩테라퓨틱스 | 세마글루타이드 또는 티르제파타이드의 개선된 의료 요법 제공을 위한 비만 및 당뇨 치료용으로써, 소수성 이온 페어링 겔레이션을 통한 초기 방출이 제어된 데포 조성물 및 이의 제조방법 |
| CN118845644B (zh) * | 2024-09-27 | 2025-01-17 | 杭州信海医药科技有限公司 | 一种司美格鲁肽注射液的制备方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK39892D0 (da) | 1992-03-25 | 1992-03-25 | Bernard Thorens | Peptid |
| DE69737479T4 (de) | 1996-08-30 | 2010-05-06 | Novo Nordisk A/S | Glp-1 derivate |
| DE60224284T2 (de) * | 2001-06-28 | 2008-12-18 | Novo Nordisk A/S | Stabile formulierung von modifiziertem glp-1 |
| JP4949838B2 (ja) | 2003-09-19 | 2012-06-13 | ノヴォ ノルディスク アー／エス | 新規ｇｌｐ−１誘導体 |
| CN1882356B (zh) | 2003-11-20 | 2015-02-25 | 诺沃挪第克公司 | 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂 |
| WO2006051110A2 (en) | 2004-11-12 | 2006-05-18 | Novo Nordisk A/S | Stable formulations of insulinoptropic peptides |
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| KR20150042304A (ko) | 2006-04-14 | 2015-04-20 | 맨카인드 코포레이션 | 글루카곤 유사 펩타이드 1 （ｇｌｐ-1） 약제학적 제제 |
| WO2008116088A1 (en) | 2007-03-20 | 2008-09-25 | Nippon Kayaku Kabushiki Kaisha | Method to monitor drug efficacy in diabetic patients using an assay for 1,5-anhydro-d-glucitol |
| JP2011504871A (ja) | 2007-06-01 | 2011-02-17 | ノボ・ノルデイスク・エー／エス | 固体又は半固体担体中にペプチド薬剤を含む自然に分散可能なプレコンセントレイト |
| WO2009030738A1 (en) | 2007-09-05 | 2009-03-12 | Novo Nordisk A/S | Glucagon-like peptide-1 derivatives and their pharmaceutical use |
| CN101842386A (zh) | 2007-09-05 | 2010-09-22 | 诺沃-诺迪斯克有限公司 | 截短的glp-1衍生物和它们的治疗用途 |
| US20100317057A1 (en) | 2007-12-28 | 2010-12-16 | Novo Nordisk A/S | Semi-recombinant preparation of glp-1 analogues |
| ES2620610T3 (es) | 2008-12-10 | 2017-06-29 | Glaxosmithkline Llc | Composiciones farmacéuticas de albiglutide |
| CN117547538A (zh) | 2009-02-13 | 2024-02-13 | 勃林格殷格翰国际有限公司 | 包含dpp-4抑制剂(利格列汀)任选地组合其它抗糖尿病药的抗糖尿病药物 |
| CN102791731B (zh) | 2009-12-16 | 2016-04-20 | 诺沃—诺迪斯克有限公司 | Glp-1类似物和衍生物 |
| CN107961377B (zh) * | 2010-05-05 | 2022-11-22 | 勃林格殷格翰国际有限公司 | 组合疗法 |
| WO2012016419A1 (zh) | 2010-08-06 | 2012-02-09 | 浙江贝达药业有限公司 | Glp-1衍生物及其应用 |
| PT2651398T (pt) | 2010-12-16 | 2018-03-09 | Novo Nordisk As | Composições sólidas compreendendo um agonista de glp-1 e um sal de ácido n-(8-(2-hidroxibenzoil)amino) caprílico |
| US20130035281A1 (en) | 2011-02-09 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| CN102718858B (zh) | 2011-03-29 | 2014-07-02 | 天津药物研究院 | 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用 |
| WO2012136790A1 (en) | 2011-04-07 | 2012-10-11 | Glaxo Group Limited | Compositions comprising fusion proteins or conjugates with an improved half -life |
| CN102229668A (zh) | 2011-06-03 | 2011-11-02 | 浙江贝达药业有限公司 | 一种glp-1衍生物及其应用 |
| US20140220134A1 (en) | 2011-06-24 | 2014-08-07 | Astrazeneca Pharamceuticals LP | Method for treating diabetes with extended release formulation of glp-1 receptor agonists |
| JP6059802B2 (ja) | 2012-07-01 | 2017-01-11 | ノヴォ ノルディスク アー／エス | 長時間作用型ｇｌｐ−１ペプチドの使用 |
-
2013
- 2013-06-21 JP JP2015519000A patent/JP6059802B2/ja active Active
- 2013-06-21 RS RS20200684A patent/RS60432B1/sr unknown
- 2013-06-21 AU AU2013286177A patent/AU2013286177B2/en active Active
- 2013-06-21 EP EP20157813.5A patent/EP3689365B1/en active Active
- 2013-06-21 PT PT137378089T patent/PT2866825T/pt unknown
- 2013-06-21 PL PL13737808.9T patent/PL2866825T3/pl unknown
- 2013-06-21 CA CA2877056A patent/CA2877056A1/en not_active Abandoned
- 2013-06-21 RU RU2018117557A patent/RU2018117557A/ru unknown
- 2013-06-21 HU HUE20157813A patent/HUE072859T2/hu unknown
- 2013-06-21 HR HRP20200889TT patent/HRP20200889T1/hr unknown
- 2013-06-21 MX MX2019008148A patent/MX376058B/es active IP Right Grant
- 2013-06-21 MX MX2014014946A patent/MX366405B/es active IP Right Grant
- 2013-06-21 BR BR112014032938A patent/BR112014032938A2/pt not_active Application Discontinuation
- 2013-06-21 PL PL20157813.5T patent/PL3689365T3/pl unknown
- 2013-06-21 RS RS20250936A patent/RS67258B1/sr unknown
- 2013-06-21 EP EP24175788.9A patent/EP4406593A3/en active Pending
- 2013-06-21 ES ES13737808T patent/ES2796839T3/es active Active
- 2013-06-21 HU HUE13737808A patent/HUE049152T2/hu unknown
- 2013-06-21 HR HRP20251088TT patent/HRP20251088T1/hr unknown
- 2013-06-21 EP EP13737808.9A patent/EP2866825B1/en not_active Revoked
- 2013-06-21 DK DK13737808.9T patent/DK2866825T3/da active
- 2013-06-21 US US14/409,493 patent/US9764003B2/en active Active
- 2013-06-21 WO PCT/EP2013/063004 patent/WO2014005858A1/en not_active Ceased
- 2013-06-21 ES ES20157813T patent/ES3041720T3/es active Active
- 2013-06-21 SI SI201331733T patent/SI2866825T1/sl unknown
- 2013-06-21 RU RU2015101826A patent/RU2657573C2/ru active
-
2014
- 2014-12-05 MX MX2020010693A patent/MX2020010693A/es unknown
-
2017
- 2017-07-21 US US15/656,042 patent/US10335462B2/en active Active
-
2018
- 2018-04-10 AU AU2018202504A patent/AU2018202504B2/en active Active
-
2020
- 2020-04-16 AU AU2020202573A patent/AU2020202573B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015522573A5 (cg-RX-API-DMAC7.html) | ||
| MX2022004041A (es) | Derivados de oxintomodulina novedosos y composicion farmaceutica para tratar la obesidad que comprende los mismos. | |
| MX2017004592A (es) | Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos. | |
| PH12018501424B1 (en) | A composition for treating diabetes or diabesity comprising oxyntomodulin analog | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| GB2491328A (en) | Immediate/delayed drug delivery | |
| NZ702801A (en) | Treatment of sanfilippo syndrome type b | |
| MX339614B (es) | Uso de ave0010 para la fabricacion de un medicamento para el tratamiento de la diabetes mellitus tipo 2. | |
| NZ714963A (en) | Compositions and methods for treating anemia | |
| JP2012193216A5 (cg-RX-API-DMAC7.html) | ||
| WO2017022962A8 (ko) | Ripk 억제제를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물 | |
| HK1206246A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| AU2018256619A1 (en) | Compounds for the treatment of obesity and methods of use thereof | |
| AU2012334804A8 (en) | Modulators of C3a receptors | |
| WO2007133796A3 (en) | Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist | |
| HK1225972A1 (zh) | 利用拉喹莫德来延缓亨廷顿氏病的进展 | |
| MY195054A (en) | Pharmaceutical Composition Comprising Mineralocorticoid Receptor Antagonist and use Thereof | |
| WO2011119649A3 (en) | Pharmaceutical compositions containing berberine for treatment or prevention of weight gain and obesity associated with anti-psychotic drugs | |
| WO2016072692A3 (ko) | 네크록스를 유효성분으로 함유하는 점막염 예방 또는 치료용 조성물 | |
| MX2018005345A (es) | Composiciones farmaceuticas de dimetil fumarato. | |
| JP2018043942A5 (cg-RX-API-DMAC7.html) | ||
| Sheehy | Ketamine/morphine | |
| WO2014071339A3 (en) | Bremelanotide therapy for female sexual dysfunction | |
| Carman | Ferric carboxymaltose | |
| JP2017514820A5 (cg-RX-API-DMAC7.html) |